SIGA Technologies, Inc. (SIGA)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$3.29+1.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Intact: The reason to own it still holds.
SIGA aims to deliver $26 million in IV TPOXX revenue by Q3 2026. Analysts expect revenue to grow about 45% next year. The stock trades cheap with a price-to-earnings ratio near 13. Free cash flow yield is positive but low.
SIGA has missed earnings several times recently. Revenue growth is uncertain and may fall short. The stock price has dropped 23.5% from its high. This shows risk in the business and execution.
The market prices in about 45% revenue growth and a fair value near $5.35. The stock trades about 32% below our fair value estimate. Our view aligns with the market on growth but sees risk in execution.
Breaks if: EPS falls below $1.05 in FY27
Breaks if: Revenue from IV TPOXX falls below $26M by Q3 2026
Breaks if: Revenue growth falls below 44.5% in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity in the healthcare sector. The current thesis state is intact, supported by strong recent financial performance and ongoing management priorities.
The market appears to have priced in some fragility due to weak execution quality, but overall valuation is considered cheap compared to peers. There is an expectations gap, indicating that some positive developments may not be fully reflected in the current valuation.
Management is focused on delivering key contracts and expanding international sales, which could support revenue growth. However, there is elevated risk due to potential guidance cuts and broader economic conditions that could impact performance.
The future performance hinges on management's ability to secure new contracts and the overall momentum in the healthcare sector. Additionally, macroeconomic factors, such as job growth and sector performance, will play a critical role in shaping outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Strong revenue supports the delivery of IV TPOXX to the U.S. Government by Q3 2026. There are no new threats impacting the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
In the next 1 to 3 years, SIGA's performance will depend on execution against management priorities and external market conditions. Not investment advice.